Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:IRON 17 October 2025 - 1 January 2026

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) shares fell 11.5% to $80.04 on Dec. 20, 2025, after a STAT News report raised doubts about the effectiveness of its lead drug bitopertin and the FDA’s fast-track voucher process. The stock traded between $71.46 and $94.60 on heavy volume after Truist Securities cited the report, fueling concerns about the viability of accelerated approval.
20 December 2025
·
Disc Medicine (NASDAQ: IRON) Stock Tumbles on Insider-Selling Headlines as Bitopertin FDA Decision Nears — News, Analyst Forecasts, and What to Watch (Dec. 19, 2025)

Disc Medicine (NASDAQ: IRON) Stock Tumbles on Insider-Selling Headlines as Bitopertin FDA Decision Nears — News, Analyst Forecasts, and What to Watch (Dec. 19, 2025)

Disc Medicine (NASDAQ: IRON) shares fell about 10% to $81 in heavy trading Friday, after a series of insider sales by executives and directors appeared in SEC filings. The drop comes ahead of an expected FDA decision on bitopertin for EPP. CEO John Quisel, director Kevin Bitterman, and William Savage all disclosed recent stock sales. The stock had closed at $90.44 the prior session.
19 December 2025
·
Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine shares jumped 25.5% to $93 on October 17, 2025, after the FDA granted a Commissioner’s National Priority Voucher for its lead drug, bitopertin. The company filed a New Drug Application for bitopertin in late September; with the voucher, an approval decision could come as soon as late December. Several analysts raised their price targets sharply following the FDA news.
17 October 2025
·

Stock Market Today

  • Evertz Technologies Fair Value Targets Lifted by Analysts on TSX
    March 20, 2026, 2:37 PM EDT. Analysts have raised the fair value estimate for Evertz Technologies (TSX:ET) from CA$14.88 to CA$17.25, reflecting a roughly 16% increase and aligning with a cluster of price targets between CA$16 and CA$17.50. Canaccord and BMO Capital have each lifted their price targets to CA$17.50, maintaining positive ratings, while RBC Capital has raised its target incrementally to CA$16 but retains a cautious Sector Perform stance. The upward revisions follow updated assumptions, including a slight dip in revenue growth to 4.16% and an improved net profit margin to 12.98%. The stock's quarterly dividend was declared at CA$0.2050 per share, payable March 2026. Investors should note the narrowed upside range and potential risks flagged, advising careful consideration of entry points and expectations.
Go toTop